Wednesday, September 10, 2025 The CCTG HD11 study, a Randomized Phase II Study of Pembrolizumab and Brentuximab Vedotin Versus GDP, Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma has closed to accrual. This purpose of this study was to determine if treatment with Pembrolizumab and Brentuximab vedotin is better or worse than the standard of care for classical Hodgkin lymphoma.For more information > CCTG HD11 members trial page.
